Ionis Pharmaceuticals, Inc.NASDAQ: IONS

Ionis to present at upcoming investor conferences

· Issued by Ionis Pharmaceuticals, Inc. via Business Wire

Summary by 6ix AI

Ionis Pharmaceuticals, Inc., a developer of RNA-targeted medicines, said its management will take part in fireside chats at four investor conferences between November 16, 2026 and December 2, 2026.

Key details

  • Conferences: UBS Global Biopharma Conference on Monday, November 16, 2026; Jefferies Global Healthcare Conference on Wednesday, November 18, 2026; Citi's 2026 Global Healthcare Conference on Tuesday, December 1, 2026; Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026.
  • The presentations will be webcast live in the Investors and Media section of the Ionis website, with replays available within 48 hours and archived for a limited time.

6ix AI wrote this summary from the release below and checked it against the release.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:

  • UBS Global Biopharma Conference on Monday, November 16, 2026
  • Jefferies Global Healthcare Conference on Wednesday, November 18, 2026
  • Citi’s 2026 Global Healthcare Conference on Tuesday, December 1, 2026
  • Piper Sandler 38th Annual Healthcare Conference on Wednesday, December 2, 2026

A live webcast of these presentations can be accessed on the Investors & Media section of the Ionis website at https://ir.ionis.com/events-and-presentations/upcoming-events. Replays will be available on the Ionis website within 48 hours and will be archived for a limited time.

About Ionis Pharmaceuticals, Inc.

For three decades, Ionis has invented medicines that bring better futures to people with serious diseases. Ionis currently has marketed medicines and a leading pipeline in neurology, cardiometabolic disease and select areas of high patient need. As the pioneer in RNA-targeted medicines, Ionis continues to drive innovation in RNA therapies in addition to advancing new approaches in gene editing. A deep understanding of disease biology and industry-leading technology propels our work, coupled with a passion and urgency to deliver life-changing advances for patients. To learn more about Ionis, visit Ionis.com and follow us on X (Twitter), LinkedIn and Instagram.

View original source (Business Wire)Ionis Pharmaceuticals, Inc. on 6ix

Earlier from Ionis Pharmaceuticals

All Ionis Pharmaceuticals news releases